Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia

被引：0
|
作者：
Bourne, Garrett [1 ]
Diebold, Kendall [1 ]
Espinoza-Gutarra, Manuel [2 ]
Al-Kadhimi, Zaid [1 ]
Bachiashvili, Kimo [2 ]
Rangaraju, Sravanti [1 ]
Vachhani, Pankit [3 ]
Bhatia, Ravi [1 ]
Jamy, Omer [4 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[3] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Div Hematol Oncol, Birmingham, AL USA
[4] Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189853
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
    Peter Paschka
    Richard F Schlenk
    Daniela Weber
    Axel Benner
    Lars Bullinger
    Michael Heuser
    Verena I Gaidzik
    Felicitas Thol
    Mridul Agrawal
    Veronica Teleanu
    Michael Lübbert
    Walter Fiedler
    Markus Radsak
    Jürgen Krauter
    Heinz-A. Horst
    Richard Greil
    Karin Mayer
    Andrea Kündgen
    Uwe Martens
    Gerhard Heil
    Helmut R Salih
    Bernd Hertenstein
    Carsten Schwänen
    Gerald Wulf
    Elisabeth Lange
    Michael Pfreundschuh
    Mark Ringhoffer
    Michael Girschikofsky
    Thomas Heinicke
    Doris Kraemer
    Gudrun Göhring
    Arnold Ganser
    Konstanze Döhner
    Hartmut Döhner
    Leukemia, 2018, 32 : 1621 - 1630
  • [42] Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia
    Rojek, Alexandra E.
    McCormick, Benjamin J.
    Cwykiel, Joanna
    Odetola, Oluwatobi
    Abaza, Yasmin
    Nai, Nhi
    Foucar, Charles E.
    Achar, Rohan K.
    Shallis, Rory M.
    Bradshaw, Danielle
    Standridge, Meaghan
    Kota, Vamsi
    Murthy, Guru Subramanian Guru
    Badar, Talha
    Patel, Anand A.
    EJHAEM, 2024, 5 (04): : 728 - 737
  • [43] Survival Is Poorer in Patients With Secondary Core-binding Factor Acute Myelogenous Leukemia Compared With De Novo Core-binding Factor Leukemia
    Borthakur, Gautam
    Lin, E.
    Jain, Nitin
    Estey, Elihu E.
    Cortes, Jorge E.
    O'Brien, Susan
    Faderl, Stefan
    Ravandi, Farhad
    Pierce, Sherry
    Kantarjian, Hagop
    CANCER, 2009, 115 (14) : 3217 - 3221
  • [44] Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia
    Prabahran, Ashvind A.
    Tacey, Mark
    Fleming, Shaun
    Strong, Danielle
    Wei, Andrew
    Tate, Courtney
    Marlton, Paula
    Wight, Joel
    Grigg, Andrew
    Tuckfield, Annabel
    Szer, Jeff
    Ritchie, David S.
    Chee, Lynette C. Y.
    BLOOD, 2015, 126 (23)
  • [45] Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia
    Fan Yang
    Li Zhang
    Bei-Bei Zhao
    Jing-Liao Zhang
    Xi-Ting Liu
    Xue Li
    Bo-Hao Tang
    Yue Zhou
    Xin-Mei Yang
    John van den Anker
    Xiao-Fan Zhu
    Wei Zhao
    Clinical Pharmacokinetics, 2022, 61 : 71 - 81
  • [46] KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia
    Chen, Xi
    Dou, Hu
    Wang, Xingjuan
    Huang, Yi
    Lu, Ling
    Bin, Junqing
    Su, Yongchun
    Zou, Lin
    Yu, Jie
    Bao, Liming
    LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 829 - 836
  • [47] Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
    Itzykson, Raphael
    Duployez, Nicolas
    Fasan, Annette
    Decool, Gauthier
    Marceau-Renaut, Alice
    Meggendorfer, Manja
    Jourdan, Eric
    Petit, Arnaud
    Lapillonne, Helene
    Micol, Jean-Baptiste
    Cornillet-Lefebvre, Pascale
    Ifrah, Norbert
    Leverger, Guy
    Dombret, Herve
    Boissel, Nicolas
    Haferlach, Torsten
    Preudhomme, Claude
    BLOOD, 2018, 132 (02) : 187 - 196
  • [48] Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
    B F Goemans
    Ch M Zwaan
    M Miller
    M Zimmermann
    A Harlow
    S Meshinchi
    A H Loonen
    K Hählen
    D Reinhardt
    U Creutzig
    G J L Kaspers
    M C Heinrich
    Leukemia, 2005, 19 : 1536 - 1542
  • [49] Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
    Hassan Awada
    Mina Abdelmalek
    Tara Cronin
    Jeffrey Baron
    Zakariya Kashour
    Farhan Azad
    Muhammad Salman Faisal
    Mark Faber
    Matthew Gravina
    Pamela J. Sung
    Steven D. Green
    Amanda Przespolewski
    James E. Thompson
    Elizabeth A. Griffiths
    Eunice S. Wang
    Blood Cancer Journal, 13
  • [50] Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
    Dolnik, Anna
    Jahn, Nikolaus
    Strang, Eric
    Cocciardi, Sibylle
    Rucker, Frank G.
    Panina, Ekaterina
    Blatte, Tamara J.
    Herzig, Julia Katharina
    Corbacioglu, Andrea
    Weber, Daniela
    Schrade, Anika
    Gaidzik, Verena I.
    Skambraks, Sabrina
    Gotze, Katharina S.
    Luebbert, Michael
    Fiedler, Walter
    Schroeder, Thomas
    Hahn, Corinna
    Thol, Felicitas
    Heuser, Michael
    Ganser, Arnold
    Paschka, Peter
    Dohner, Hartmut
    Dohner, Konstanze
    Bullinger, Lars
    BLOOD, 2020, 136
12345